AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M

AVITA Medical, Inc.

Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.
Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.
Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.
Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AVITA Medical, Inc. reported first quarter ended March 31, 2026 results: revenue approximately $19.3 million, net income $10.6 million, EPS $0.35 per basic and diluted share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: approximately $19.3 million
Net income: $10.6 million
EPS: $0.35 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates • Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx ® and improved RECELL ® utilization as reimbursement dynamics normalize •

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.